Bioequivalence study of cilostazol 100-mg orally disintegrated tablets and cilostazol 100-mg conventional tablets in healthy adult male subjects

Setsuo Hasegawa, Junko Inomata, Hisashi Akiyoshi, Yoshinobu Yasuda, Naoko Shimofurutani, Miyuki Yuasa, Yoshie Tuji, Eiichi Saitoh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cilostazol orally disintegrated tablets (ODT) are a newly developed formulation for easier swallowing by patients with swallowing disorders that make it difficult for them to take tablets with water. The bioequivalence of one cilostazol 100-mg ODT ingested with or without water and one cilostazol 100-mg conventional tablet ingested with water was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 3-period crossover study. Thirty six subjects were enrolled, and 32 subjects completed the study. The differences in the mean log-transformed AUC 60h and C max values between the ODT without water and the conventional tablet (ODT without water-conventional tablet, point estimates) were both log (0.94), with respective 90% confidence intervals of log (0.88) to log (1.00) and log (0.87) to log (1.02). The differences in the mean log-transformed AUC 60h and C max values between the ODT with water and the conventional tablet (ODT with water-conventional tablet, point estimates) were both log (0.98), with respective 90% confidence intervals of log (0.92) to log (1.04) and log (0.91) to log (1.06). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on the above results, one cilostazol 100-mg ODT, when administered either with or without water, was judged to be bioequivalent to one cilostazol 100-mg conventional tablet. All adverse events observed in all groups were mild or moderate in severity and were resolved. Deaths or other serious adverse events or clinically significant adverse events did not occur.

Original languageEnglish
Pages (from-to)805-812
Number of pages8
JournalJapanese Pharmacology and Therapeutics
Volume37
Issue number10
Publication statusPublished - 01-12-2009

Fingerprint

Therapeutic Equivalency
Tablets
Water
cilostazol
Area Under Curve
Confidence Intervals
Deglutition
Deglutition Disorders
Cross-Over Studies

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hasegawa, Setsuo ; Inomata, Junko ; Akiyoshi, Hisashi ; Yasuda, Yoshinobu ; Shimofurutani, Naoko ; Yuasa, Miyuki ; Tuji, Yoshie ; Saitoh, Eiichi. / Bioequivalence study of cilostazol 100-mg orally disintegrated tablets and cilostazol 100-mg conventional tablets in healthy adult male subjects. In: Japanese Pharmacology and Therapeutics. 2009 ; Vol. 37, No. 10. pp. 805-812.
@article{7887d4ed67a24f69b8206c6c3e959a2b,
title = "Bioequivalence study of cilostazol 100-mg orally disintegrated tablets and cilostazol 100-mg conventional tablets in healthy adult male subjects",
abstract = "Cilostazol orally disintegrated tablets (ODT) are a newly developed formulation for easier swallowing by patients with swallowing disorders that make it difficult for them to take tablets with water. The bioequivalence of one cilostazol 100-mg ODT ingested with or without water and one cilostazol 100-mg conventional tablet ingested with water was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 3-period crossover study. Thirty six subjects were enrolled, and 32 subjects completed the study. The differences in the mean log-transformed AUC 60h and C max values between the ODT without water and the conventional tablet (ODT without water-conventional tablet, point estimates) were both log (0.94), with respective 90{\%} confidence intervals of log (0.88) to log (1.00) and log (0.87) to log (1.02). The differences in the mean log-transformed AUC 60h and C max values between the ODT with water and the conventional tablet (ODT with water-conventional tablet, point estimates) were both log (0.98), with respective 90{\%} confidence intervals of log (0.92) to log (1.04) and log (0.91) to log (1.06). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on the above results, one cilostazol 100-mg ODT, when administered either with or without water, was judged to be bioequivalent to one cilostazol 100-mg conventional tablet. All adverse events observed in all groups were mild or moderate in severity and were resolved. Deaths or other serious adverse events or clinically significant adverse events did not occur.",
author = "Setsuo Hasegawa and Junko Inomata and Hisashi Akiyoshi and Yoshinobu Yasuda and Naoko Shimofurutani and Miyuki Yuasa and Yoshie Tuji and Eiichi Saitoh",
year = "2009",
month = "12",
day = "1",
language = "English",
volume = "37",
pages = "805--812",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "10",

}

Bioequivalence study of cilostazol 100-mg orally disintegrated tablets and cilostazol 100-mg conventional tablets in healthy adult male subjects. / Hasegawa, Setsuo; Inomata, Junko; Akiyoshi, Hisashi; Yasuda, Yoshinobu; Shimofurutani, Naoko; Yuasa, Miyuki; Tuji, Yoshie; Saitoh, Eiichi.

In: Japanese Pharmacology and Therapeutics, Vol. 37, No. 10, 01.12.2009, p. 805-812.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bioequivalence study of cilostazol 100-mg orally disintegrated tablets and cilostazol 100-mg conventional tablets in healthy adult male subjects

AU - Hasegawa, Setsuo

AU - Inomata, Junko

AU - Akiyoshi, Hisashi

AU - Yasuda, Yoshinobu

AU - Shimofurutani, Naoko

AU - Yuasa, Miyuki

AU - Tuji, Yoshie

AU - Saitoh, Eiichi

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Cilostazol orally disintegrated tablets (ODT) are a newly developed formulation for easier swallowing by patients with swallowing disorders that make it difficult for them to take tablets with water. The bioequivalence of one cilostazol 100-mg ODT ingested with or without water and one cilostazol 100-mg conventional tablet ingested with water was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 3-period crossover study. Thirty six subjects were enrolled, and 32 subjects completed the study. The differences in the mean log-transformed AUC 60h and C max values between the ODT without water and the conventional tablet (ODT without water-conventional tablet, point estimates) were both log (0.94), with respective 90% confidence intervals of log (0.88) to log (1.00) and log (0.87) to log (1.02). The differences in the mean log-transformed AUC 60h and C max values between the ODT with water and the conventional tablet (ODT with water-conventional tablet, point estimates) were both log (0.98), with respective 90% confidence intervals of log (0.92) to log (1.04) and log (0.91) to log (1.06). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on the above results, one cilostazol 100-mg ODT, when administered either with or without water, was judged to be bioequivalent to one cilostazol 100-mg conventional tablet. All adverse events observed in all groups were mild or moderate in severity and were resolved. Deaths or other serious adverse events or clinically significant adverse events did not occur.

AB - Cilostazol orally disintegrated tablets (ODT) are a newly developed formulation for easier swallowing by patients with swallowing disorders that make it difficult for them to take tablets with water. The bioequivalence of one cilostazol 100-mg ODT ingested with or without water and one cilostazol 100-mg conventional tablet ingested with water was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 3-period crossover study. Thirty six subjects were enrolled, and 32 subjects completed the study. The differences in the mean log-transformed AUC 60h and C max values between the ODT without water and the conventional tablet (ODT without water-conventional tablet, point estimates) were both log (0.94), with respective 90% confidence intervals of log (0.88) to log (1.00) and log (0.87) to log (1.02). The differences in the mean log-transformed AUC 60h and C max values between the ODT with water and the conventional tablet (ODT with water-conventional tablet, point estimates) were both log (0.98), with respective 90% confidence intervals of log (0.92) to log (1.04) and log (0.91) to log (1.06). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on the above results, one cilostazol 100-mg ODT, when administered either with or without water, was judged to be bioequivalent to one cilostazol 100-mg conventional tablet. All adverse events observed in all groups were mild or moderate in severity and were resolved. Deaths or other serious adverse events or clinically significant adverse events did not occur.

UR - http://www.scopus.com/inward/record.url?scp=73849104399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849104399&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:73849104399

VL - 37

SP - 805

EP - 812

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - 10

ER -